Contrast-induced acute kidney injury after primary percutaneous coronary intervention: Results from the HORIZONS-AMI substudy

European Heart Journal

Volumn 35, Issue 23, 2014, Pages 1533-1540

  Narula, Amar ^a   Mehran, Roxana ^b,c   Weisz, Giora ^c,d,e   Dangas, George D ^b,c   Yu, Jennifer ^b   Généreux, Philippe ^c,d,f   Nikolsky, Eugenia ^g   Brener, Sorin J ^c,h   Witzenbichler, Bernhard ⁱ   Guagliumi, Giulio ^j   Clark, Avery E ^k   Fahy, Martin ^c   Xu, Ke ^c   Brodie, Bruce R ^l   Stone, Gregg W ^c,d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e SHAARE ZEDEK MEDICAL CENTER   (Israel)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^h NEW YORK METHODIST HOSPITAL   (United States)

ⁱ Amper Kliniken AG   (Germany)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k BROWN UNIVERSITY   (United States)

^l MOSES CONE HEALTH SYSTEM   (United States)

more..

Author keywords

Contrast media; Kidney; Myocardial infarction

Indexed keywords

CONTRAST MEDIUM; CREATININE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLEEDING; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG ELUTING STENT; FEMALE; HUMAN; INCIDENCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; ACUTE KIDNEY FAILURE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CLINICAL TRIAL; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; OSMOLARITY; POSTOPERATIVE HEMORRHAGE; RECURRENT DISEASE; STENT;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSMOLAR CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; RECURRENCE; STENTS; STROKE; TREATMENT OUTCOME;

EID: 84902591259     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu063     Document Type: Article

References (36)

1. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
2. Brown JR, DeVries JT, Piper WD, Robb JF, Hearne MJ, Ver Lee PM, Kellet MA, Watkins MW, Ryan TJ, Silver MT, Ross CS, MacKenzie TA, O'Connor GT, Malenka DJ. Serious renal dysfunction after percutaneous coronary interventions can be predicted. Am Heart J 2008;155:260-266.
3. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-1217.
4. Briguori C, Visconti G, Ricciardelli B, Condorelli G. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention 2011;6:1117-1122.
5. Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, Thompson CA. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2009;2:1116-1124.
6. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensivemeta-analysis. Catheter Cardiovasc Interv 2005;64:471-479.
7. Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS-A multicenter prospective controlled trial. Int J Cardiol 2012;155:418-423.
8. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354: 2773-2782.
9. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, Grazi M, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. AmJ Med 2006;119:155-162.
10. Mehran R, Nikolsky E, Kirtane AJ, Caixeta A,Wong SC, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Kim YH, Fahy M, Dangas GD. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. JACC Cardiovasc Interv 2009;2:415-421.
11. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004;148:690-695.
12. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, Isono T, Sutani Y, Yuasa F, Iwasaka T. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol 2011;107:1604-1608.
13. Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007;49:1283-1288.
14. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/ Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008;156:776-782.
15. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189-3196.
16. Ueda H, Yamada T, Masuda M, Okuyama Y, Morita T, Furukawa Y, Koji T, Iwasaki Y, Okada T, Kawasaki M, KuramotoY, NaitoT, FujimotoT, Komuro I, Fukunami M. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol 2011;107:1163-1167.
17. Zhao JL, Yang YJ, Zhang YH, You SJ, Wu YJ, Gao RL. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008;126:435-436.
18. Toso A, Leoncini M, Maioli M, Tropeano F, Villani S, Bellandi F. Early High-dose Rosuvastatin for Contrast-induced Nephropathy Prevention in Acute Coronary Syndrome. American College of Cardiology. San Francisco, California, 2013.
19. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010;55:2201-2209.
20. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230.
21. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ,Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-1159.
22. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44: 1780-1785.
23. Sgura FA, Bertelli L, Monopoli D, Leuzzi C, Guerri E, Sparta I, Politi L, Aprile A, Amato A, Rossi R, Biondi-Zoccai G, Sangiorgi GM, Modena MG. Mehran contrast-induced nephropathy risk score predicts short-and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv 2010;3:491-498.
24. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 2008;156:44-56.
25. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010; 122:2451-2455.
26. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, Sharma SK, Labinaz M, Gelormini JL, Barrett BJ. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009;4: 1162-1169.
27. James MT, GhaliWA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, Manns BJ, KlarenbachSW, Hemmelgarn BR. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011;123: 409-416.
28. Chong E, Poh KK, Liang S, Soon CY, Tan HC. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol 2010;23: 451-459.
29. Bouzas-Mosquera A, Vazquez-Rodriguez JM, Calvino-Santos R, Peteiro-Vazquez J, Flores-Rios X, Marzoa-Rivas R, Pinon-Esteban P, Aldama-Lopez G, Salgado-Fernandez J, Vazquez-Gonzalez N, Castro-Beiras A. Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors and prognosis. Rev Esp Cardiol 2007;60:1026-1034.
30. Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, Plehn G, Trappe HJ, Meissner A. Contrast mediuminduced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009;98:765-772.
31. Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, Sakuma T, Yoshida S, Sutani Y, Iwasaka T. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2010;105:624-628.
32. Marenzi G, Cabiati A, Bertoli SV, Assanelli E, Marana I, De Metrio M, Rubino M, Moltrasio M, Grazi M, Campodonico J, Milazzo V, Veglia F, Lauri G, Bartorelli AL. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. Am J Cardiol 2013;111:816-822.
33. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW Jr. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000;101:2172-2177.
34. Bertrand ME, Esplugas E, Piessens J, RaschW. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: a multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 2000;101:131-136.
35. Le Feuvre C, Batisse A, Collet JP, Batisse JP, Choussat R, Beygui F, Helft G, Montalescot G, Metzger JP. Cardiac events afterlow osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty. Catheter Cardiovasc Interv 2006;67:852-858.
36. Bellemain-Appaix A, Beygui F, Lesty C, Gupta S, Silvain J, Le Feuvre C, Cayla G, Allali Y, Montalescot G, Collet JP. Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: the PEPCIT study. Catheter Cardiovasc Interv 2012;79:823-833.